Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 5/20 | 0.46 |
| ▸ | CNR1 | P21554 | 4/20 | 0.44 |
| ▸ | CNR2 | P34972 | 4/20 | 0.44 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4114890 | 0.81 | CNR1 (0.50) | CNR1CNR2CXCR5HPGDSHCRTR1 | |
| SCHEMBL5847102 | 0.79 | PTPN1 (0.53) | GRM2HPGD | |
| SCHEMBL14065381 | 0.79 | CNR1 (0.44) | CNR1CNR2CXCR5HPGDSHCRTR1 | |
| SCHEMBL13513601 | 0.77 | CNR1 (0.43) | CNR1CNR2CXCR5HPGDSHCRTR1 | |
| SCHEMBL4116945 | 0.77 | HPGDS (0.58) | CNR1CNR2CXCR5HPGDSHCRTR1 | |
| SCHEMBL9000004 | 0.76 | PTPN1 (0.61) | CNR1CNR2HPGD | |
| SCHEMBL4109693 | 0.76 | PTPN1 (0.61) | CNR1CNR2HPGD | |
| SCHEMBL4103684 | 0.75 | CNR1 (0.42) | CNR1CNR2CXCR5HCRTR1HCRTR2 | |
| SCHEMBL29392762 | 0.74 | CNR1 (0.47) | CNR1CNR2CXCR5HCRTR1HCRTR2 | |
| SCHEMBL401068 | 0.74 | CNR1 (0.47) | CNR1CNR2CXCR5HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | PROSIDION LIMITED (GB) | 2009-09-03 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| US-7429607-B2 | 5-HT2B receptor antagonists | ASTERAND UK LIMITED (GB) | 2008-09-30 | — | — | US | disclosed |
| EP-1474140-B1 | 2-OXAZOLAMINES AND THEIR USE AS 5-HT2B RECEPTOR ANTAGONISTS | ASTERAND UK LTD (GB) | 2007-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221645-A1 | Dihydroimidazothiazole Derivatives | TPH1, HTR3B, HTR1A | GRM2 418/4885CNR1 202/4885CNR2 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.